Recent studies on BRCA1/BRCA2 have concluded that a germline mutation in BRCA1 or BRCA2 was associated with improved survival in ovarian cancer patients and BRCA2 carriers had the best prognosis (40–, 42). This evidence concerns the gene BRCA2 and ovarian cancer.